Willis-Knighton Health System is looking for participants for a clinical study to examine whether a new drug reduces symptoms of COVID-19 infection and reduces the need for medical visits or hospitalization due to the virus.
The new drug is composed of monoclonal antibodies. Security will be assessed.
The health care formula is one of one hundred sites in the United States and the only one in the region involved in this study.
“We are proud to have been chosen as a clinical study for this trial, which is supported by the federal government,” says Joseph Bocchini, MD, an infectious disease specialist at Willis-Knighton.
“If shown to reduce the severity of COVID-19 infection, monoclonal antibodies may become the first recommended outpatient remedy for other people inflamed by COVID-19.”
Dr. Bocchini and Clint Wilson, MD of Family Medical Associates are the researchers in the study.
Those eligible to participate must be over 18 years of age and have a lab-confirmed COVID-19 with symptoms such as fever, dry cough, shortness of breath, sore throat, etc. Patients recently hospitalized or hospitalized by COVID -19 are not eligible, says Carrie Kay, registered nurse, CCRC, clinical studies manager at WK Physician Network.
The duration of the exam is 30 days. Participants will get a single dose of one of the two formulations of the drug examined or a placebo at the WK COVID Research Infusion Center and will be monitored at home and evaluated by fitness professionals they examine.
There are no fees for the player or insurance for visits, medicines or follow-up. Instead, each patient will get a small allowance for the time needed to participate.
“We believe this is one of the most promising features as a gateway to keep patients as outpatients until a vaccine is approved,” Kay says.
To learn more about this exam and eligibility criteria, call Carrie Kay at (318) 455-9730 or https://www.wkhs.com/clinical-trials/ and click ON COVID.